Summary
Updated Aug 31, 2026
Pontifax Management 4 G.P. (2015) Ltd. is 10% Owner of Keros Therapeutics, Inc. (KROS). 2 SEC Form 4 filings on record, most recently on 15 October 2025. Most recent open-market trade: sold $2.76M of KROS on 15 October 2025. Lifetime open-market purchases: $15.00M. Lifetime open-market sales: $84.98M.
Recent Transactions
6Every recent SEC Form 4 transaction Pontifax Management 4 G.P. (2015) Ltd. has reported, most recent first.
Trading Pattern
InsiderAlpha's records for Pontifax Management 4 G.P. (2015) Ltd. go back to 2025: 2 primary Form 4 filings, an average of 1.0 per year. The typical open-market purchase is $15.00M (1 buy totaling $15.00M). The largest single buy on record is $15.00M of LBRX in 2025. Sales side: 4 recorded sales totaling $84.98M, so the filing history runs sell-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Pontifax Management 4 G.P. (2015) Ltd. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ADAR1 Capital Management, LLC - $95.66M of KROS open-market activity in the last 12 months
- Deep Track Biotechnology Master Fund, Ltd. - $60.00M of LBRX open-market activity in the last 12 months
- Ran Nussbaum - $15.00M of LBRX open-market activity in the last 12 months
- Vida Ventures GP III, L.L.C. - $5.00M of LBRX open-market activity in the last 12 months
- Esther Cho - $124K of KROS open-market activity in the last 12 months
- Jasbir Seehra - $113K of KROS open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
What is Pontifax Management 4 G.P. (2015) Ltd.?
Pontifax Management 4 G.P. (2015) Ltd. is an investment firm, tracked as 10% Owner of Keros Therapeutics, Inc. (KROS). InsiderAlpha holds 2 primary Form 4 filings for it, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Pontifax Management 4 G.P. (2015) Ltd. last file a Form 4?
The most recent primary Form 4 on record is dated 15 October 2025, one of 2 filings going back to 2025.
Has Pontifax Management 4 G.P. (2015) Ltd. been buying or selling stock?
Recorded transactions: 1 open-market purchase ($15.00M) and 4 open-market sales ($84.98M) across all tracked filings.
Where can I see all of Pontifax Management 4 G.P. (2015) Ltd.'s SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Pontifax Management 4 G.P. (2015) Ltd. and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial